T2 Biosystems, Inc. is an early-stage company that is developing transformative in vitro and in vivo diagnostic products to monitor human health and response to therapy. The Company’s proprietary detection technology was developed by a group of leading academic researchers at both the Massachusetts General Hospital and M.I.T. Unlike the approaches used in conventional diagnostics, T2’s technology applies across the gamut of medically relevant analytes including proteins, nucleic acids, lipids, small molecule compounds, and micro-organisms. In addition, T2 Biosystem’s approach enables the development of products with continuous and real-time monitoring capability. Flagship co-led the Series A financing in 2006. Flagship Partner Douglas Levinson serves as CEO and Managing Partner, Noubar Afeyan serves as Director.